PACB
Pacific Biosciences of California
1.60$
+2.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 61.4% | 42.4% | 51.3% | 62.9% | 68.1% | 62.0% | 58.7% | 54.9% | 61.8% | 73.7% | 75.8% | 68.3% | |
| 38.6% | 57.6% | 48.7% | 37.1% | 31.9% | 38.0% | 41.3% | 45.1% | 38.2% | 26.3% | 24.2% | 31.7% | |
| 79.6% | 65.1% | 74.5% | 69.9% | 79.6% | 65.6% | 81.3% | 86.5% | 150.4% | 93.3% | 87.6% | 60.8% | |
| 62.8% | 48.7% | 52.7% | 63.3% | 80.7% | 83.1% | 92.3% | 95.1% | 125.4% | 84.2% | 113.6% | 88.4% | |
| 142.4% | 113.8% | 127.2% | 133.1% | 160.4% | 148.7% | 173.6% | 206.3% | 277.6% | 193.1% | 332.2% | 380.1% | |
| -103.7% | -31.4% | -78.5% | -96.1% | -128.4% | -110.6% | -132.3% | -161.2% | -239.4% | -166.8% | -308.0% | -348.5% | |
| 4.7% | 3.2% | 3.6% | 3.1% | 3.1% | 2.9% | 0.3% | 9.6% | 11.4% | 7.2% | 8.7% | 4.3% | |
| -109.2% | -34.2% | -82.0% | -98.6% | -130.4% | -92.6% | 37.3% | -210.6% | -244.9% | -158.7% | -201.0% | -341.3% | |
| 3.9% | -0.4% | 3.7% | -5.4% | 1.1% | -6.9% | -8.8% | -71.8% | -13.5% | -5.7% | 0.2% | 0.2% | |
| -109.2% | -34.2% | -82.0% | -98.6% | -130.4% | -92.6% | 37.3% | -138.9% | -244.9% | -153.0% | -201.2% | -341.5% | |
| -97.6% | -27.0% | -74.2% | -86.5% | -118.2% | -78.7% | 49.4% | -192.1% | -220.0% | -135.2% | -157.6% | -21.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.